Tenofovir alafenamide for hepatitis B: evolution or revolution? [PDF]
The Lancet Gastroenterology & Hepatology, 2016 Chronic hepatitis B infection remains a global health burden despite existence of an effective vaccine. Infection with chronic hepatitis B and its sequelae lead to almost 800 000 deaths annually. Over the past decades, treatment of chronic hepatitis B has evolved considerably.
Brouwer, Willem P.; id_orcid
openaire +5 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2023 Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are prodrugs of the nucleotide analogue tenofovir, which acts intracellularly to inhibit HIV replication.
Aida N. Kawuma +8 more
doaj +2 more sources
Chiral Analysis of the Key Intermediates of Tenofovir Alafenamide Fumarate
Pharmaceutical Fronts, 2023 (R)-Tenofovir phenyl ester ((R)-1) and (R)-tenofovir diphenyl ester ((R)-2) are key intermediates for the practical synthesis of tenofovir alafenamide fumarate, which is a mainstay antiretroviral for the treatment of chronic hepatitis B and HIV-1 ...
Man Li, Ting Zhou, Qing-Wen Zhang
doaj +2 more sources
Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date [PDF]
HIV/AIDS: Research and Palliative Care, 2018 Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract ...
Hill L, Smith SR, Karris MY
doaj +2 more sources
Drug Design, Development and Therapy, 2017 Eiichi Ogawa,1 Norihiro Furusyo,1 Mindie H Nguyen2 1Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan; 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto,
Ogawa E, Furusyo N, Nguyen MH
doaj +1 more source
An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate [PDF]
Drugs in R&DBackground and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus.
Derek E. Murrell +8 more
doaj +2 more sources
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. [PDF]
, 2023 Tenofovir alafenamide is gradually replacing tenofovir disoproxil fumarate, both prodrugs of tenofovir, in HIV prevention and treatment. There is thus an interest in describing tenofovir pharmacokinetics (PK) and its variability in people living with HIV
Andre, P. +9 more
core +2 more sources
Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity. [PDF]
, 2018 Although the use of tenofovir alafenamide (TAF), a new prodrug of tenofovir, was safe and efficacious in clinical trials, real-world data from multimorbid individuals are scarce.
Walti, Laura Naëmi +7 more
core +3 more sources
Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing [PDF]
, 2021 From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-
Okochi, Hideaki +25 more
core +1 more source
Терапевтический архив, 2021 Aim. To analyze the features of drugs provision for special groups of treatment-nave HIV-infected patients initiating antiretroviral treatment with fixed dose combination (FDC) for once-daily single-tablet regimen, in Russian healthcare setting ...
Elena A. Pyadushkina, Elena V. Derkach
doaj +1 more source